(ILMN) Illumina - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US4523271090
Stock: Sequencers, Arrays, Reagents, Kits, Services
Total Rating 57
Risk 89
Buy Signal -0.89
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 66.0% |
| Relative Tail Risk | -6.11% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.11 |
| Alpha | -20.46 |
| Character TTM | |
|---|---|
| Beta | 1.073 |
| Beta Downside | 0.868 |
| Drawdowns 3y | |
|---|---|
| Max DD | 68.94% |
| CAGR/Max DD | -0.21 |
Description: ILMN Illumina January 02, 2026
Illumina (NASDAQ: ILMN) develops and sells sequencing- and array-based platforms and consumables for genomic analysis across a global customer base that includes research institutions, clinical labs, pharma/biotech firms, and consumer-genomics companies. Its product portfolio spans next-generation sequencing instruments, whole-genome and targeted-sequencing kits, genotyping arrays, and non-invasive prenatal testing solutions, supported by reagent kits, flow cells, and library-prep services.
Key recent metrics: 2023 revenue reached $5.6 billion, up ~9 % YoY, driven by a 15 % increase in consumables sales as sequencing-throughput volumes rise. The company’s cost-per-genome has fallen below $200, reinforcing its competitive edge in the rapidly expanding clinical-diagnostics market, where NGS adoption is projected to grow at a CAGR of ~20 % through 2030. A notable sector driver is the surge in personalized-medicine pipelines, which fuels demand for high-throughput, low-error-rate sequencing platforms.
For a deeper, data-focused assessment of Illumina’s valuation dynamics, you may find the analytical tools on ValueRay worth exploring.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 850.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.14 > 0.02 and ΔFCF/TA 2.88 > 1.0 |
| NWC/Revenue: 39.24% < 20% (prev 27.42%; Δ 11.82% < -1%) |
| CFO/TA 0.16 > 3% & CFO 1.08b > Net Income 850.0m |
| Net Debt (1.06b) to EBITDA (1.46b): 0.73 < 3 |
| Current Ratio: 2.08 > 1.5 & < 3 |
| Outstanding Shares: last quarter (154.0m) vs 12m ago -3.75% < -2% |
| Gross Margin: 66.49% > 18% (prev 0.65%; Δ 6584 % > 0.5%) |
| Asset Turnover: 67.07% > 50% (prev 69.36%; Δ -2.29% > 0%) |
| Interest Coverage Ratio: 11.86 > 6 (EBITDA TTM 1.46b / Interest Expense TTM 100.0m) |
Altman Z'' 3.47
| A: 0.26 (Total Current Assets 3.29b - Total Current Liabilities 1.58b) / Total Assets 6.64b |
| B: -0.11 (Retained Earnings -726.0m / Total Assets 6.64b) |
| C: 0.18 (EBIT TTM 1.19b / Avg Total Assets 6.47b) |
| D: 0.87 (Book Value of Equity 3.08b / Total Liabilities 3.56b) |
| Altman-Z'' Score: 3.47 = A |
Beneish M -3.02
| DSRI: 1.15 (Receivables 854.0m/751.0m, Revenue 4.34b/4.37b) |
| GMI: 0.98 (GM 66.49% / 65.44%) |
| AQI: 0.91 (AQ_t 0.34 / AQ_t-1 0.37) |
| SGI: 0.99 (Revenue 4.34b / 4.37b) |
| TATA: -0.03 (NI 850.0m - CFO 1.08b) / TA 6.64b) |
| Beneish M-Score: -3.02 (Cap -4..+1) = AA |
What is the price of ILMN shares?
As of February 09, 2026, the stock is trading at USD 119.72 with a total of 4,449,448 shares traded.
Over the past week, the price has changed by -15.17%, over one month by -17.90%, over three months by -1.64% and over the past year by +14.03%.
Over the past week, the price has changed by -15.17%, over one month by -17.90%, over three months by -1.64% and over the past year by +14.03%.
Is ILMN a buy, sell or hold?
Illumina has received a consensus analysts rating of 3.68.
Therefor, it is recommend to hold ILMN.
- StrongBuy: 7
- Buy: 5
- Hold: 11
- Sell: 2
- StrongSell: 0
What are the forecasts/targets for the ILMN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 136.5 | 14% |
| Analysts Target Price | 136.5 | 14% |
| ValueRay Target Price | 106.8 | -10.8% |
ILMN Fundamental Data Overview February 08, 2026
P/E Trailing = 21.967
P/E Forward = 26.0417
P/S = 4.2913
P/B = 7.4975
P/EG = 0.622
Revenue TTM = 4.34b USD
EBIT TTM = 1.19b USD
EBITDA TTM = 1.46b USD
Long Term Debt = 1.49b USD (from longTermDebt, last quarter)
Short Term Debt = 499.0m USD (from shortTermDebt, last quarter)
Debt = 2.48b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.06b USD (from netDebt column, last quarter)
Enterprise Value = 19.46b USD (18.40b + Debt 2.48b - CCE 1.42b)
Interest Coverage Ratio = 11.86 (Ebit TTM 1.19b / Interest Expense TTM 100.0m)
EV/FCF = 20.72x (Enterprise Value 19.46b / FCF TTM 939.0m)
FCF Yield = 4.83% (FCF TTM 939.0m / Enterprise Value 19.46b)
FCF Margin = 21.63% (FCF TTM 939.0m / Revenue TTM 4.34b)
Net Margin = 19.58% (Net Income TTM 850.0m / Revenue TTM 4.34b)
Gross Margin = 66.49% ((Revenue TTM 4.34b - Cost of Revenue TTM 1.46b) / Revenue TTM)
Gross Margin QoQ = 67.04% (prev 67.59%)
Tobins Q-Ratio = 2.93 (Enterprise Value 19.46b / Total Assets 6.64b)
Interest Expense / Debt = 2.02% (Interest Expense 50.0m / Debt 2.48b)
Taxrate = 11.64% (44.0m / 378.0m)
NOPAT = 1.05b (EBIT 1.19b * (1 - 11.64%))
Current Ratio = 2.08 (Total Current Assets 3.29b / Total Current Liabilities 1.58b)
Debt / Equity = 0.80 (Debt 2.48b / totalStockholderEquity, last quarter 3.08b)
Debt / EBITDA = 0.73 (Net Debt 1.06b / EBITDA 1.46b)
Debt / FCF = 1.13 (Net Debt 1.06b / FCF TTM 939.0m)
Total Stockholder Equity = 2.52b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.13% (Net Income 850.0m / Total Assets 6.64b)
RoE = 33.70% (Net Income TTM 850.0m / Total Stockholder Equity 2.52b)
RoCE = 29.56% (EBIT 1.19b / Capital Employed (Equity 2.52b + L.T.Debt 1.49b))
RoIC = 24.22% (NOPAT 1.05b / Invested Capital 4.33b)
WACC = 8.91% (E(18.40b)/V(20.88b) * Re(9.87%) + D(2.48b)/V(20.88b) * Rd(2.02%) * (1-Tc(0.12)))
Discount Rate = 9.87% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -1.58%
[DCF Debug] Terminal Value 78.36% ; FCFF base≈847.0m ; Y1≈1.04b ; Y5≈1.78b
Fair Price DCF = 159.1 (EV 25.37b - Net Debt 1.06b = Equity 24.31b / Shares 152.8m; r=8.91% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 48.58 | EPS CAGR: 6.39% | SUE: 0.60 | # QB: 0
Revenue Correlation: -50.43 | Revenue CAGR: -1.42% | SUE: 3.20 | # QB: 2
EPS next Quarter (2026-03-31): EPS=1.07 | Chg30d=-0.047 | Revisions Net=+3 | Analysts=11
EPS current Year (2026-12-31): EPS=5.13 | Chg30d=+0.066 | Revisions Net=+4 | Growth EPS=+6.0% | Growth Revenue=+4.5%
EPS next Year (2027-12-31): EPS=5.81 | Chg30d=+0.018 | Revisions Net=+1 | Growth EPS=+13.2% | Growth Revenue=+4.9%
P/E Forward = 26.0417
P/S = 4.2913
P/B = 7.4975
P/EG = 0.622
Revenue TTM = 4.34b USD
EBIT TTM = 1.19b USD
EBITDA TTM = 1.46b USD
Long Term Debt = 1.49b USD (from longTermDebt, last quarter)
Short Term Debt = 499.0m USD (from shortTermDebt, last quarter)
Debt = 2.48b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.06b USD (from netDebt column, last quarter)
Enterprise Value = 19.46b USD (18.40b + Debt 2.48b - CCE 1.42b)
Interest Coverage Ratio = 11.86 (Ebit TTM 1.19b / Interest Expense TTM 100.0m)
EV/FCF = 20.72x (Enterprise Value 19.46b / FCF TTM 939.0m)
FCF Yield = 4.83% (FCF TTM 939.0m / Enterprise Value 19.46b)
FCF Margin = 21.63% (FCF TTM 939.0m / Revenue TTM 4.34b)
Net Margin = 19.58% (Net Income TTM 850.0m / Revenue TTM 4.34b)
Gross Margin = 66.49% ((Revenue TTM 4.34b - Cost of Revenue TTM 1.46b) / Revenue TTM)
Gross Margin QoQ = 67.04% (prev 67.59%)
Tobins Q-Ratio = 2.93 (Enterprise Value 19.46b / Total Assets 6.64b)
Interest Expense / Debt = 2.02% (Interest Expense 50.0m / Debt 2.48b)
Taxrate = 11.64% (44.0m / 378.0m)
NOPAT = 1.05b (EBIT 1.19b * (1 - 11.64%))
Current Ratio = 2.08 (Total Current Assets 3.29b / Total Current Liabilities 1.58b)
Debt / Equity = 0.80 (Debt 2.48b / totalStockholderEquity, last quarter 3.08b)
Debt / EBITDA = 0.73 (Net Debt 1.06b / EBITDA 1.46b)
Debt / FCF = 1.13 (Net Debt 1.06b / FCF TTM 939.0m)
Total Stockholder Equity = 2.52b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.13% (Net Income 850.0m / Total Assets 6.64b)
RoE = 33.70% (Net Income TTM 850.0m / Total Stockholder Equity 2.52b)
RoCE = 29.56% (EBIT 1.19b / Capital Employed (Equity 2.52b + L.T.Debt 1.49b))
RoIC = 24.22% (NOPAT 1.05b / Invested Capital 4.33b)
WACC = 8.91% (E(18.40b)/V(20.88b) * Re(9.87%) + D(2.48b)/V(20.88b) * Rd(2.02%) * (1-Tc(0.12)))
Discount Rate = 9.87% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -1.58%
[DCF Debug] Terminal Value 78.36% ; FCFF base≈847.0m ; Y1≈1.04b ; Y5≈1.78b
Fair Price DCF = 159.1 (EV 25.37b - Net Debt 1.06b = Equity 24.31b / Shares 152.8m; r=8.91% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 48.58 | EPS CAGR: 6.39% | SUE: 0.60 | # QB: 0
Revenue Correlation: -50.43 | Revenue CAGR: -1.42% | SUE: 3.20 | # QB: 2
EPS next Quarter (2026-03-31): EPS=1.07 | Chg30d=-0.047 | Revisions Net=+3 | Analysts=11
EPS current Year (2026-12-31): EPS=5.13 | Chg30d=+0.066 | Revisions Net=+4 | Growth EPS=+6.0% | Growth Revenue=+4.5%
EPS next Year (2027-12-31): EPS=5.81 | Chg30d=+0.018 | Revisions Net=+1 | Growth EPS=+13.2% | Growth Revenue=+4.9%